GlassScriptPhysician profile
Lanette Smith
NPI 1306951637
$1,463.95
in general payments reported to CMS, 2019-2025
28 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2024: $522 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vector Surgical, LLC | $300.11 | 2024 | |
| Merck Sharp & Dohme LLC | $183.24 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Bard Peripheral Vascular, INC. | $113.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $84.40 | 2024-2025 | |
| Janssen Biotech, INC. | $68.58 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Sobi, INC | $63.94 | 2025 | |
| Genmab U.S., INC. | $56.30 | 2024-2025 | Tivdak |
| Lilly USA, LLC | $49.70 | 2024-2025 | Verzenio |
| Stemline Therapeutics INC. | $49.33 | 2024-2025 | Orserdu |
| Springworks Therapeutics, INC. | $46.89 | 2024-2025 | Ogsiveo |
| Astrazeneca Pharmaceuticals LP | $43.12 | 2025 | Imfinzi |
| Incyte Corporation | $37.27 | 2025 | Zynyz, Monjuvi, Jakafi |
| Emd Serono, INC. | $36.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.18 | 2025 | |
| Kite Pharma, INC. | $30.20 | 2025 | Yescarta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $29.94 | 2025 | Brukinsa |
| Abbvie INC. | $26.41 | 2025 | |
| Genzyme Corporation | $24.87 | 2025 | |
| Astellas Pharma US INC | $24.79 | 2025 | Xtandi |
| Daiichi Sankyo INC. | $24.47 | 2025 | Injectafer |
| Adaptive Biotechnologies Corporation | $21.43 | 2025 | Clonoseq |
| Recordati_rare_diseases_inc. | $19.99 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $17.23 | 2025 | |
| Eisai INC. | $16.29 | 2024 | |
| Pharmaessentia USA Corporation | $15.66 | 2025 | Besremi |
| Tolmar, INC. | $15.31 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $15.31 | 2025 | Rubraca |
| Legend Biotech USA INC. | $14.86 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanette Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.